Platinum-resistant ovarian cancer treatment is entering a new research phase with Rina-S, an investigational FRα-targeted antibody-drug conjugate that reported a 45.9% response rate in RAINFOL-01. This patient-focused update explains the trial results, safety concerns, FRα findings, prior-treatment relevance, and why Phase 3 confirmation is essential before Rina-S can be considered a proven standard option.